Dyax/Genzyme Phase II Hereditary Angioedema Therapy On Clinical Hold; FDA Questioning Rat Deaths

The companies submitted to FDA primate data and interim results from the now-halted Phase II EDEMA2 study. The rat deaths could be related to DX-88 bolus administration, Dyax suggested.